ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 203 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,194,111 | -7.2% | 57,299 | +6.7% | 0.14% | -34.3% |
Q2 2023 | $1,286,690 | +191.8% | 53,724 | +99.5% | 0.21% | +142.0% |
Q3 2022 | $441,000 | +66.4% | 26,935 | +146.6% | 0.09% | +151.4% |
Q1 2022 | $265,000 | +22.1% | 10,923 | +107.7% | 0.04% | -25.5% |
Q3 2020 | $217,000 | -55.1% | 5,258 | -47.3% | 0.05% | -86.7% |
Q2 2020 | $483,000 | -87.9% | 9,968 | -89.3% | 0.35% | +67.3% |
Q4 2019 | $3,983,000 | -19.5% | 93,099 | -32.3% | 0.21% | -19.2% |
Q3 2019 | $4,948,000 | +555.4% | 137,469 | +386.7% | 0.26% | +552.5% |
Q2 2019 | $755,000 | +254.5% | 28,244 | +255.5% | 0.04% | +263.6% |
Q1 2019 | $213,000 | -84.0% | 7,944 | -77.6% | 0.01% | -93.3% |
Q3 2017 | $1,334,000 | +13240.0% | 35,403 | +11941.8% | 0.16% | +8050.0% |
Q1 2017 | $10,000 | -96.9% | 294 | -97.3% | 0.00% | -96.9% |
Q4 2016 | $320,000 | -37.6% | 11,094 | -23.0% | 0.06% | -81.7% |
Q4 2015 | $513,000 | +288.6% | 14,400 | +260.0% | 0.35% | +203.5% |
Q3 2015 | $132,000 | -62.2% | 4,000 | -63.6% | 0.12% | -80.2% |
Q4 2014 | $349,000 | – | 11,000 | – | 0.58% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |